# "Novel therapeutic approaches to improve fracture healing while reducing pain behavior"

> **NIH VA I01** · RLR VA MEDICAL CENTER · 2022 · —

## Abstract

Veterans with fractures suffer from injury-associated pain as well as post-operative surgical pain. The
occurrence of a fracture contributes to acute pain and is largely manifested by mechanical, inflammatory, and
neuropathic components. The LEAP study of high-energy lower extremity trauma showed that acute pain, in
the recovery period after severe trauma, is the single largest predictor of long-term chronic pain 5-10 years
after injury. There are 2 main strategies to treat trauma-induced and post-surgical pain: opioids and
nonsteroidal anti-inflammatory drugs (NSAIDs). Neither drug class completely alleviates pain, and both have
negative side effects. Opioids, beyond eliciting cognitive impairment, are commonly associated with tolerance
and addiction. NSAIDs are commonly used in combination with opioids following thoracic/abdominal surgery
but use of this drug class for fracture pain is discouraged in the U.S. due to negative effects on skeletal health
and healing of the injured skeleton. It is unclear which drug class is less destructive to the bone repair process
but prevention of nonunion is paramount in the treatment of fractures as it places additional burden on the
patient and the healthcare system due to prolonged pain and disability. Therefore, identification of therapies
which improve both the bone healing process and diminish the fracture-associated pain is warranted. Our
recent data demonstrate that mRNA levels of Sirtuin-1 (Sirt1, an NAD+ class III histone deacetylase) are
robustly elevated during fracture healing. Fracture healing is impaired with age, bone loss, inflammation, and
with neurodegeneration. Importantly, Sirt1 improves all of these conditions; however, to our knowledge, with
the exception of our studies, nobody has specifically examined the effects of Sirt1 on fracture repair. Here we
show that pharmacological activation of Sirt1 by SRT1720 allows for improved fracture healing while reducing
pain behaviors. Based on these observations we hypothesize that activation of Sirt1 in mesenchymal
lineage cells and associated nervous system interactions will enhance bone healing and reduce pain in
mice by regulating inflammation. The proposed work will test this hypothesis, and may provide evidence that
pharmacologic activation of Sirt1 could serve both as a novel bone healing agent and post-fracture analgesic
agent. In Aim 1, we will demonstrate that SRT1720 can improve bone healing and reduce pain behaviors and
inflammation in mice, and determine which cells require Sirt1 activation by SRT1720 for successful bone
healing, reduced pain behaviors, and reduced inflammation. In Aim 2, we will determine how SRT1720
treatment, mesenchymal lineage cells, and primary afferent sensory neurons (PANs) regulate inflammation,
and we will examine the crosstalk between mesenchymal lineage cells and PANs. Successful accomplishment
of these Aims will demonstrate the utility of using Sirt1 activators as novel bone healing and post-fracture
anal...

## Key facts

- **NIH application ID:** 10426446
- **Project number:** 1I01RX003552-01A2
- **Recipient organization:** RLR VA MEDICAL CENTER
- **Principal Investigator:** Melissa A Kacena
- **Activity code:** I01 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2022
- **Award amount:** —
- **Award type:** 1
- **Project period:** 2022-04-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10426446

## Citation

> US National Institutes of Health, RePORTER application 10426446, "Novel therapeutic approaches to improve fracture healing while reducing pain behavior" (1I01RX003552-01A2). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10426446. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*